Company / Depreciation & Amortization
Vivos Therapeutics, Inc. Depreciation & Amortization History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$581.0K
FY2025
5-year range
$581.0K / $733.0K
FY2021-FY2025
Trend
-6.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has declined for 3 consecutive years, from $733,000 in FY2022 to $581,000 in FY2025.
Based on SEC 10-K filings.
$581,000 in FY2025 with a 5-year CAGR of -5.0%.
Improved from $669,000 to $581,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -7.5%
- 5-Year CAGR
- -5.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- Vivos Therapeutics, Inc.'s depreciation & amortization has declined for 3 consecutive years.
- 5-year CAGR of -5.0%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 6.4% year-over-year.
- Peak depreciation & amortization was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $581.0K | -6.4% |
| FY2024 | $621.0K | -7.2% |
| FY2023 | $669.0K | -8.7% |
| FY2022 | $733.0K | +2.1% |
| FY2021 | $718.0K | -4.4% |
| FY2020 | $751.2K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026